Objective:To investigate the clinical efficacy of dapagliflozin in the treatment of ejection fraction preserving heart failure(HFpEF)combined with paroxysmal atrial fibrillation(PAF).Methods:Two-hundred pa-tients with HFpEF combined with PAF in Anhui No.2 Provincial People's Hospital from January 2023 to April 2023 were selected,and the patients were divided into the experimental group and the control group with 100 cases each by random number table method.Patients in the control group were treated with conventional drugs,and those in the experimental group were treated with conventional drugs combined with dapagliflozin.The monthly occurrence of atrial fibrillation and the longest duration of each atrial fibrillation,plasma N-terminal B-type natri-uretic peptide precursor(NT-proBNP),interleukin-6(IL-6),left ventricular mass fraction(LVMI),left atrial vol-ume index(LAVI),24-hour average ventricular rate,and QTc interval before treatment and 3,6 and 9 months af-ter treatment,as well as adverse reactions during treatment,and re-hospitalization for heart failure after 9 months of treatment were observed.Results:After 3,6,and 9 months of treatment,the monthly occurrence of atrial fi-brillation,the longest duration of each atrial fibrillation,NT-proBNP,IL-6,LVMI,LAVI,24-hour mean ven-tricular rate,and QTc interval were significantly improved in both the control and experimental groups,and the degree of improvement increased with the prolongation of treatment time.At the same time,the improvement in the experimental group was significantly higher than that in the control group(all P＜0.05).After 9 months of treatment,the re-admission rate of heart failure in the experimental group was lower than that in the control group(38％vs 25％,x2=3.916,P=0.048).During the treatment period,there was no statistically significant differ-ence in the incidence of adverse reactions between the two groups(9％vs 7％,x2=0.270,P=0.603).Conclu-sion:Dapagliflozin can improve cardiac function,alleviate atrial and ventricular remodeling,improve long-term prognosis and has good safety in HFpEF patients with PAF.
dapagliflozinheart failure with preserved ejection fractionparoxysmal atrial fibrillationcardiac function
维普
万方数据
